31676-55-8

Basic information

• Product Name: 3-HYDROXY-5-PHENYLPYRIDINE
• Synonyms: 3-HYDROXY-5-PHENYLPYRIDINE
• CAS NO: 31676-55-8
• Molecular Formula: C₁₁H₉NO
• Molecular Weight: 171.2
• Mol File: 31676-55-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 430.7 °C at 760 mmHg
• Flash Point: 214.3 °C
• Appearance: /
• Density: 1.169 g/cm³
• Vapor Pressure: 5.06E-08mmHg at 25°C
• Refractive Index: 1.611
• CAS DataBase Reference: 3-HYDROXY-5-PHENYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-HYDROXY-5-PHENYLPYRIDINE(31676-55-8)
• EPA Substance Registry System: 3-HYDROXY-5-PHENYLPYRIDINE(31676-55-8)

Safety Data

• Hazardous Substances Data: 31676-55-8(Hazardous Substances Data)

Usage

General Description

3-Hydroxy-5-phenylpyridine is a chemical compound with the molecular formula C11H9NO. It is a heterocyclic aromatic compound with a pyridine ring substituted with a hydroxyl group at the 3-position and a phenyl group at the 5-position. 3-HYDROXY-5-PHENYLPYRIDINE is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds. It also has potential applications in the field of medicinal chemistry due to its pharmacological properties. Additionally, 3-Hydroxy-5-phenylpyridine has been identified as a potential scaffold for drug development, making it a significant chemical compound for research and development in the pharmaceutical industry.

InChI:InChI=1/C11H9NO/c13-11-6-10(7-12-8-11)9-4-2-1-3-5-9/h1-8,13H

Upstream product

• 53698-52-5 3-methoxy-5-phenylpyridine 
• 74115-13-2 5-bromopyridine-3-ol 
• 100-58-3 phenylmagnesium bromide 
• 7732-18-5 water 
• 142137-17-5 3-bromo-5-phenylpyridine 

Relevant articles and documents

P2Et Phosphazene: A Mild, Functional Group Tolerant Base for Soluble, Room Temperature Pd-Catalyzed C-N, C-O, and C-C Cross-Coupling Reactions

The non-nucleophilic organic superbase P2Et phosphazene can enable a broad range of palladium-catalyzed cross-coupling reactions, including C-C, C-N, and C-O couplings of aryl chlorides, bromides, and iodides at room temperature. The mildness a

Selective Co/Ti cooperatively catalyzed biaryl couplings of aryl halides with aryl metal reagents

Various aryl bromides or chlorides, including those bearing a free COOH, OH, CONHR, and SO2NHR group, coupled with aryl magnesium or lithium reagents in the presence of 7.5 mol % CoCl2/15 mol % PBu3 and substoichiometric Ti(OEt)4 (40 mol % to ArM) at room temperature in high yields with high chemo- and regioslectivity. This simple reaction represents the first example of Co/Ti cooperative catalysis which plays a key role in suppressing undesired homocouplings.

8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS

The present invention relates to a 8-azabicyclo[3.2.1]octane derivative of Formula I, wherein R1 is H or C1-5alkyl; Y is O, S or O(CH2)m; m is 1 or 2; n is 0 or 1; Ar1 is phenylene or pyridylene, said phenylene and pyridylene being 1,3-linked with respect to O and when n is 1 with Y and when n is 0 with Ar2, said phenylene or pyridylene being optionally substituted with one or two substituents independently selected from halogen, C1-5alkyl, C1-5alkoxy, C3-6cycloalkyl, C2-5alkenyl, C2-5alkynyl, phenyl, CN and hydroxy, wherein said C1-5alkyl and C1-5alkoxy are optionally substituted with one to three halogens and wherein the oxygen of said hydroxy is optionally bonded to Ar2 to form a 5-membered ring; Ar2 is phenyl or a 5-6 membered heteroaryl, said phenyl or 5-6 membered heteroaryl being optionally substituted with one to three substituents independently selected from halogen, C1-5alkyl, C1-5alkoxy, CN, CONR2R3, CO2R4, NHCOR5 and hydroxy, wherein said C1-5alkyl and C1-5alkoxy are optionally substituted with one to three halogens and wherein the oxygen of said hydroxy is optionally bonded to Ar1 to form a 5-membered ring; R2-R4 are independently H or C1-5alkyl and R5 is C1-5alkyl, or a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising a 8- azabicyclo[3.2.1]octane derivative according to the present invention in admixture with one or more pharmaceutically acceptable auxiliaries and to the use of a 8- azabicyclo[3.2.1]octane derivative according to the present invention in therapy.